Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Drug Profile

Research programme: exportin 1-mediated nuclear export inhibitors - Karyopharm Therapeutics

Alternative Names: CRM1-mediated nuclear export inhibitors - Karyopharm; KPT-185; KPT-350; KPT-SINE; SINE™ compounds; XPO1-mediated nuclear export inhibitors - Karyopharm

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Karyopharm Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; HIV infections; Inflammation; Influenza virus infections; Wounds

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Amyotrophic lateral sclerosis; Autoimmune disorders; Brain injuries; Cancer; Duchenne muscular dystrophy; Epilepsy; HIV infections; Inflammation; Multiple sclerosis; Skin disorders; Wounds

Most Recent Events

  • 25 Jan 2018 Biogen enters into an agreement with Karyopharm Therapeutics for purchase of KPT 350 and other assets for neurological disorders
  • 22 Apr 2017 Pharmacodynamics data from a preclinical study in Duchenne Muscular Dystrophy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 16 Mar 2017 KPT 350 is available for licensing in World as of 16 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top